Nchi: Afrika Kusini
Lugha: Kiingereza
Chanzo: South African Health Products Regulatory Authority (SAHPRA)
Quatrom
Q-MED DIAZEPAM Injection 10 mg/2 mL SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): Q-MED DIAZEPAM Injection 10 mg/2 mL COMPOSITION: Each 2 mL ampoule contains 10 mg of diazepam with 5% m/v benzoate buffer, 1,5% v/v benzyl alcohol and 19,2% v/v ethanol. PHARMACOLOGICAL CLASSIFICATION: A 2.6 Tranquillizers PHARMACOLOGICAL ACTION: The effect of diazepam, a benzodiazepine, results from its action on the central nervous system ie. sedation, hypnosis, decreased anxiety, muscle relaxation, anterograde amnesia and anticonvulsant activity. Elimination follows a biphasic pattern, with a rapid distribution phase, followed by a prolonged terminal elimination phase of 1 to 2 days. The half life of its principal metabolite, desmethyldiazepam, is 2 to 5 days. It is excreted in the urine. In addition to crossing the blood-brain barrier, diazepam and its metabolites also cross the placental barrier and are excreted in breast milk. INDICATIONS: Diazepam is used in the treatment of anxiety and tension states as a sedative and pre- medication, in the control of muscle spasm as in tetanus, in the management of alcohol withdrawal syndrome. It can also be used for the control of status epilepticus. Diazepam is only indicated when the disorder is severe, disabling or subjecting the individual to extreme stress. CONTRA-INDICATIONS: Diazepam is contra-indicated in patients with known hypersensitivity to benzodiazepines. Caution should be observed when giving diazepam to patients with impaired liver, kidney or respiratory function. Elderly and debilitated patients are specially sensitive to its side-effects. Infants may be unable to metabolize diazepam. The effects of diazepam may be enhanced by alcohol, barbiturates, narcotics, and other depressants of the central nervous system. Benzodiazepi Soma hati kamili